PFG Private Wealth Management LLC Makes New Investment in Astrazeneca Plc $AZN

PFG Private Wealth Management LLC purchased a new position in shares of Astrazeneca Plc (NYSE:AZN) during the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 3,231 shares of the company’s stock, valued at approximately $297,000.

Other institutional investors have also recently made changes to their positions in the company. Binnacle Investments Inc increased its stake in Astrazeneca by 21.8% during the 3rd quarter. Binnacle Investments Inc now owns 660 shares of the company’s stock worth $51,000 after buying an additional 118 shares during the period. Chapin Davis Inc. boosted its position in Astrazeneca by 3.3% in the 3rd quarter. Chapin Davis Inc. now owns 3,795 shares of the company’s stock valued at $291,000 after buying an additional 120 shares during the period. 44 Wealth Management LLC boosted its position in Astrazeneca by 0.7% in the 3rd quarter. 44 Wealth Management LLC now owns 16,722 shares of the company’s stock valued at $1,283,000 after buying an additional 124 shares during the period. CoreCap Advisors LLC grew its stake in shares of Astrazeneca by 30.6% in the third quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock worth $41,000 after acquiring an additional 125 shares in the last quarter. Finally, Highline Wealth Partners LLC increased its position in shares of Astrazeneca by 32.0% during the third quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock worth $41,000 after acquiring an additional 129 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Astrazeneca Trading Up 1.7%

Shares of Astrazeneca stock opened at $197.20 on Wednesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.72 and a current ratio of 0.94. Astrazeneca Plc has a 52 week low of $122.48 and a 52 week high of $212.71. The company has a market capitalization of $305.84 billion, a price-to-earnings ratio of 33.97, a P/E/G ratio of 1.46 and a beta of 0.32.

Astrazeneca Announces Dividend

The business also recently announced a dividend, which was paid on Monday, March 23rd. Investors of record on Friday, February 20th were given a $1.595 dividend. This represents a dividend yield of 156.0%. The ex-dividend date of this dividend was Friday, February 20th. Astrazeneca’s dividend payout ratio (DPR) is 66.26%.

Analysts Set New Price Targets

AZN has been the topic of several analyst reports. Citigroup initiated coverage on Astrazeneca in a research note on Tuesday, January 27th. They issued a “buy” rating on the stock. Morgan Stanley restated an “overweight” rating and set a $103.00 price target on shares of Astrazeneca in a report on Wednesday, December 3rd. Barclays reaffirmed an “overweight” rating on shares of Astrazeneca in a research report on Tuesday, January 6th. Weiss Ratings began coverage on Astrazeneca in a research note on Wednesday, March 11th. They issued a “buy (b)” rating for the company. Finally, HSBC restated a “buy” rating and set a $108.00 target price on shares of Astrazeneca in a research note on Wednesday, December 10th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $95.75.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.